Abstract

BackgroundWith the second largest tuberculosis (TB) burden globally, China is committed to actively engage in international TB clinical trials to contribute to global TB research. However, lack of research capacity among local sites has been identified as a barrier.Main textThe China Tuberculosis Clinical Trials Consortium (CTCTC) was initiated by Beijing Chest Hospital with investment from the US National Institutes of Health and technical support from Family Health International 360 in 2013, as a nationwide collaborative clinical trial network to strengthen selected clinical site research capacity and attract TB clinical trials. The program aims to: 1) recruit leading hospitals that care for TB patients; 2) conduct on-site assessment to identify capacity gaps and needs for improvement; 3) design and deliver capacity building activities; 4) attract and deliver high quality results for TB clinical trials.A total of 24 sites have joined CTCTC, covering 20 provinces in China. Twenty-two sites have been accredited by the National Medical Products Administration (NMPA) to be qualified to conduct TB clinical trials. The onsite assessment, extensive trainings among the CTCTC sites and young investigators have resulted in better understanding and improvement of the site capacity in conducting TB clinical trials. The establishment and growth of the CTCTC network has benefited from the good leadership, effective international cooperation and local commitment. Issues in human resources, regulatory environment and sustainability have been challenging the network from continuing growth. Clinical researchers have full-time clinical responsibilities in China and it is thus important to build a cadre of other human resources to assist. The regulatory environment is becoming friendlier in China to introduce international clinical trials to the CTCTC network.ConclusionsThe CTCTC, with mature management structure and sustainable development model, which are distilled five key lessons for other developing countries or investigators of interest. They are the respectively using assessment-based approach to design tailored training package, understanding the availability of clinical researchers, providing solutions to maintain sustainability, understanding local regulatory environments and working with an international organization with local on-site team, respectively. Although, the experiences and capacity of China’s TB hospitals in conducting clinical research vary. Considerable efforts to continue building the capacity are still needed, although the gap is smaller for a few top-tier hospitals.

Highlights

  • Introduction to Good Clinical Laboratory Practice (GCLP)STREAM (The Evaluation of a Standard Treatment Regimen of AntiTuberculosis Drugs for Patients with MDR-TB) Trial Lab TrainingProject-based workshop Data managementData management in clinical trial/researchOnline & workshopPrinciples of Biostatistics and Data Management in Clinical Research WorkshopCase Report Form design and database set upData quality management and monitoringSafety data management and monitoringClinical data collectionQuality management

  • With good access to TB patients, China is committed to actively engage in international TB clinical trials to contribute to the global TB research development

  • With limited experiences in conducting international TB clinical trials, there has been high demand for capacity building in China as well as other TB high-burden developing countries

Read more

Summary

Introduction

Introduction to GCLPSTREAM (The Evaluation of a Standard Treatment Regimen of AntiTuberculosis Drugs for Patients with MDR-TB) Trial Lab TrainingProject-based workshop Data managementData management in clinical trial/researchOnline & workshopPrinciples of Biostatistics and Data Management in Clinical Research WorkshopCase Report Form design and database set upData quality management and monitoringSafety data management and monitoringClinical data collectionQuality management. With the second largest tuberculosis (TB) burden globally, China is committed to actively engage in international TB clinical trials to contribute to global TB research. Building new tools requires multiple high-quality clinical trial sites with experienced investigators and good patient access. With good access to TB patients, China is committed to actively engage in international TB clinical trials to contribute to the global TB research development. With limited experiences in conducting international TB clinical trials, there has been high demand for capacity building in China as well as other TB high-burden developing countries. The specific objectives of this article are to: 1) summarize the establishment, achievements, challenges, lessons and future development of the CTCTC program in China; 2) disseminate the unique experiences and lessons learnt to other TB high-burden developing countries which may have plan to establish similar network and capacity building program; 3) bring CTCTC to the international TB community for future collaborations

Objectives
Methods
Findings
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.